Nurix Therapeutics to Participate in Upcoming Investor Conferences
07 Novembro 2023 - 6:01PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with hematologic malignancies and
solid tumors, today announced that Arthur T. Sands, M.D., Ph.D.,
Nurix’s president and chief executive officer, will participate in
the following conferences in November:
- Stifel Healthcare
ConferenceFireside chat: Tuesday, November 14, 2023, from
4:45 – 5:15 p.m. ET
- Piper Sandler Healthcare
ConferenceFireside chat: Wednesday, November 29, 2023,
from 3:00 – 3:25 p.m. ET
The events will be webcast live and may be accessed via a link
in the Investors section of the Nurix website under Events and
Presentations. Archived copies of the webcasts will be available on
the Nurix website for approximately 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
medicines based on the modulation of cellular protein levels as a
novel treatment approach for cancer and other challenging diseases.
Leveraging extensive expertise in E3 ligases together with
proprietary DNA-encoded libraries, Nurix has built DELigase, an
integrated discovery platform, to identify and advance novel drug
candidates targeting E3 ligases, a broad class of enzymes that can
modulate proteins within the cell. Nurix’s drug discovery approach
is to either harness or inhibit the natural function of E3 ligases
within the ubiquitin-proteasome system to selectively decrease or
increase cellular protein levels. Nurix’s wholly owned, clinical
stage pipeline includes targeted protein degraders of Bruton’s
tyrosine kinase, a B-cell signaling protein, and inhibitors of
Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that
regulates activation of multiple immune cell types including T cell
and NK cells. Nurix is headquartered in San Francisco, California.
For additional information visit http://www.nurixtx.com.
Contacts:
Investors Silinda Neou Nurix
Therapeutics ir@nurixtx.com
Elizabeth Wolffe, Ph.D. Wheelhouse Life Science
Advisors lwolffe@wheelhouselsa.com
Media Aljanae Reynolds Wheelhouse
Life Science Advisors areynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Nurix Therapeutics (NASDAQ:NRIX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024